Wei, Zheng <br/><br/>
HBsAg is an independent prognostic factor in diffuse large B cell lymphoma patients in rituximab era: result from a multicenter retrospective analysis in China.  [electronic resource] 

 -  Medical oncology (Northwood, London, England)  Mar 2014 
 - 845 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study 
<br/><br/><label>ISSN: </label>1559-131X 
<br/><br/><label>Standard No.: </label>10.1007/s12032-014-0845-3  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antibodies, Monoclonal, Murine-Derived--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>China<br/>Cyclophosphamide--administration & dosage<br/>Doxorubicin--administration & dosage<br/>Female<br/>Follow-Up Studies<br/>Hepatitis B--complications<br/>Hepatitis B Surface Antigens--metabolism<br/>Hepatitis B virus--genetics<br/>Humans<br/>Lymphoma, Large B-Cell, Diffuse--drug therapy<br/>Male<br/>Middle Aged<br/>Neoplasm Staging<br/>Prednisone--administration & dosage<br/>Prognosis<br/>Retrospective Studies<br/>Rituximab<br/>Survival Rate<br/>Vincristine--administration & dosage